NCT01052259 - Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Chronic Rejection

Interventions

DRUG

Deoxyspergualin

100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.

Trial Locations (8)

010-8543

Akita University School of Medicine, Akita

812-8582

Graduate School of Medicine Sciences, Kyushu University, Fukuoka

501-1194

Gifu University Graduate School of Medicine, Gifu

060-8604

Sapporo City General Hospital, Sapporo

565-0871

Osaka University Graduate School of Medicine, Suita

335-0023

Toda Central General Hospital, Toda

143-8541

Toho University Graduate School of Medicine, Ōta-ku

162-8666

Tokyo Women's Medical University, Shinjuku-ku